Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

An engineered human follistatin variant: insights into the pharmacokinetic and pharmocodynamic relationships of a novel molecule with broad therapeutic potential.

Datta-Mannan A, Yaden B, Krishnan V, Jones BE, Croy JE.

J Pharmacol Exp Ther. 2013 Mar;344(3):616-23. doi: 10.1124/jpet.112.201491. Epub 2012 Dec 17. Erratum in: J Pharmacol Exp Ther. 2015 Aug;354(2):238.

2.

Follistatin: a novel therapeutic for the improvement of muscle regeneration.

Yaden BC, Croy JE, Wang Y, Wilson JM, Datta-Mannan A, Shetler P, Milner A, Bryant HU, Andrews J, Dai G, Krishnan V.

J Pharmacol Exp Ther. 2014 May;349(2):355-71. doi: 10.1124/jpet.113.211169. Epub 2014 Mar 13.

3.

Insights into the Impact of Heterogeneous Glycosylation on the Pharmacokinetic Behavior of Follistatin-Fc-Based Biotherapeutics.

Datta-Mannan A, Huang L, Pereira J, Yaden B, Korytko A, Croy JE.

Drug Metab Dispos. 2015 Dec;43(12):1882-90. doi: 10.1124/dmd.115.064519. Epub 2015 Sep 9.

4.
5.

Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy.

Rose FF Jr, Mattis VB, Rindt H, Lorson CL.

Hum Mol Genet. 2009 Mar 15;18(6):997-1005. doi: 10.1093/hmg/ddn426. Epub 2008 Dec 12.

6.

Progesterone stimulates expression of follistatin splice variants Fst288 and Fst315 in the mouse uterus.

Craythorn RG, Winnall WR, Lederman F, Gold EJ, O'Connor AE, de Kretser DM, Hedger MP, Rogers PA, Girling JE.

Reprod Biomed Online. 2012 Mar;24(3):364-74. doi: 10.1016/j.rbmo.2011.12.004. Epub 2011 Dec 20.

PMID:
22285243
7.

Follistatin-related protein and follistatin differentially neutralize endogenous vs. exogenous activin.

Sidis Y, Tortoriello DV, Holmes WE, Pan Y, Keutmann HT, Schneyer AL.

Endocrinology. 2002 May;143(5):1613-24.

PMID:
11956142
8.

Crystal structures of the heparan sulfate-binding domain of follistatin. Insights into ligand binding.

Innis CA, Hyvönen M.

J Biol Chem. 2003 Oct 10;278(41):39969-77. Epub 2003 Jul 16.

9.

Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice.

Nakatani M, Takehara Y, Sugino H, Matsumoto M, Hashimoto O, Hasegawa Y, Murakami T, Uezumi A, Takeda S, Noji S, Sunada Y, Tsuchida K.

FASEB J. 2008 Feb;22(2):477-87. Epub 2007 Sep 24.

PMID:
17893249
10.

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.

Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR.

Methods. 2014 Jan 1;65(1):114-26. doi: 10.1016/j.ymeth.2013.06.035. Epub 2013 Jul 17.

PMID:
23872058
11.

Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.

Monnet C, Jorieux S, Souyris N, Zaki O, Jacquet A, Fournier N, Crozet F, de Romeuf C, Bouayadi K, Urbain R, Behrens CK, Mondon P, Fontayne A.

MAbs. 2014 Mar-Apr;6(2):422-36. doi: 10.4161/mabs.27854. Epub 2014 Jan 15.

12.

Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects.

Liem-Moolenaar M, de Boer P, Timmers M, Schoemaker RC, van Hasselt JG, Schmidt S, van Gerven JM.

Br J Clin Pharmacol. 2011 Jun;71(6):886-98. doi: 10.1111/j.1365-2125.2011.03936.x.

13.

Heparin and activin-binding determinants in follistatin and FSTL3.

Sidis Y, Schneyer AL, Keutmann HT.

Endocrinology. 2005 Jan;146(1):130-6. Epub 2004 Oct 7.

PMID:
15471966
14.

Expression of myostatin and follistatin in Mdx mice, an animal model for muscular dystrophy.

Abe S, Soejima M, Iwanuma O, Saka H, Matsunaga S, Sakiyama K, Ide Y.

Zoolog Sci. 2009 May;26(5):315-20. doi: 10.2108/zsj.26.315.

PMID:
19715499
15.

Overexpression of mouse follistatin causes reproductive defects in transgenic mice.

Guo Q, Kumar TR, Woodruff T, Hadsell LA, DeMayo FJ, Matzuk MM.

Mol Endocrinol. 1998 Jan;12(1):96-106.

PMID:
9440814
16.

A novel role for fibronectin type I domain in the regulation of human hematopoietic cell adhesiveness through binding to follistatin domains of FLRG and follistatin.

Maguer-Satta V, Forissier S, Bartholin L, Martel S, Jeanpierre S, Bachelard E, Rimokh R.

Exp Cell Res. 2006 Feb 15;312(4):434-42. Epub 2005 Dec 5.

PMID:
16336961
17.

The heparin binding site of follistatin is involved in its interaction with activin.

Sumitomo S, Inouye S, Liu XJ, Ling N, Shimasaki S.

Biochem Biophys Res Commun. 1995 Mar 8;208(1):1-9.

PMID:
7887917
18.

Targeting myostatin for therapies against muscle-wasting disorders.

Tsuchida K.

Curr Opin Drug Discov Devel. 2008 Jul;11(4):487-94. Review.

PMID:
18600566
19.

Regulation of muscle mass by follistatin and activins.

Lee SJ, Lee YS, Zimmers TA, Soleimani A, Matzuk MM, Tsuchida K, Cohn RD, Barton ER.

Mol Endocrinol. 2010 Oct;24(10):1998-2008. doi: 10.1210/me.2010-0127. Epub 2010 Sep 1.

Supplemental Content

Support Center